What Théa Pharma does

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, headquartered at 37 rue Georges Besse in Clermont-Ferrand, France, and operating under the legal entity Théa Pharma S.A.S. The company sells prescription and over-the-counter ophthalmic products — eye drops, gels, ointments, eyelid hygiene solutions, antibiotics, and ocular nutrition supplements — addressing ten therapeutic areas including glaucoma, dry eye, ocular allergy, infection, inflammation, anesthesia, mydriasis, ocular herpes, nutrition, and eyelid hygiene. Its core proprietary technology is the ABAK multi-dose bottle system, invented by Théa in the 1990s after ten years of research, which was the first delivery system capable of providing preservative-free ophthalmic drops in a multi-dose container; this platform anchors a portfolio that emphasizes preservative-free formulations and includes branded lines such as the BLEPHA family (BLEPHASOL, BLEPHAGEL, BLEPHADERM, BLEPHADEMODEX, BLEPHACLEAN, BLEPHA EYEBAG), antibiotic treatments (APROKAM, AZYTER), and the Nutrof nutritional supplement range.

The company is privately held and controlled by the Chibret family, with founder Henri Chibret and his descendant Jean-Frédéric Chibret currently serving as President. Théa operates through an enterprise field sales motion targeting ophthalmologists and eye care professionals, with products distributed via pharmacies, hospitals, and eye care clinics rather than direct-to-consumer channels; revenue is generated through one-time sale of pharmaceutical products across 24+ countries spanning Europe, North America, and South America. Pricing is not publicly disclosed and certain formulations require prescription. The company emphasizes 100% European manufacturing and runs the Théa Academy professional education platform alongside participation in major congresses (ESCRS, AAO, EVER) for medical engagement. Recent strategic activity includes the August 2025 inauguration of a Stockholm office for the Nordic region, April 2026 membership in the Initiative Pharma French industry alliance, and a February 2026 greenhouse gas reduction roadmap aligned with international climate objectives.

No revenue, headcount, or funding data is publicly disclosed, and the company shows no evidence of AI/ML capability development, M&A activity, or external institutional investment.

Name

Théa Pharma

Legal name

Théa Pharma S.A.S.

Website

https://theapharma.fr

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, selling preservative-free eye drops, eyelid hygiene solutions, and ocular nutrition products to ophthalmologists and eye care professionals across more than 20 countries via pharmacy distribution.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Eye, Ear & Nasal Care (HLAIADAF)

Keywords

• Ophthalmic pharmaceuticals
• Preservative-free eye drops
• Eyelid hygiene products
• Ocular therapeutics
• Ophthalmic drug delivery

Headquarters

HQ city

Clermont-ferrand

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Ophthalmic pharmaceuticals: Théa generates revenue through the sale of prescription and OTC ophthalmic pharmaceutical products including eye drops, gels, ointments, and eyelid hygiene products for various eye conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, manufacturing and selling a comprehensive portfolio of preservative-free ophthalmic products including eye drops, gels, ointments, eyelid hygiene solutions, and ocular nutrition supplements. Its core proprietary technology is the ABAK multi-dose bottle system, which enables delivery of preservative-free eye drops in multi-dose containers. Products cover 10 ocular health domains: infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, ocular nutrition, herpes, and eyelid hygiene.

Product overview

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, offering a comprehensive portfolio of eye care products. The company provides treatments across multiple therapeutic areas including infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, and ocular nutrition. Théa's products are primarily preservative-free formulations delivered through innovative delivery systems. Key product lines include the ABAK® multi-dose preservative-free bottle technology, the BLEPHA® family for eyelid hygiene and care (BLEPHASOL®, BLEPHAGEL®, BLEPHADERM®, BLEPHADEMODEX®, BLEPHACLEAN®), antibiotic treatments like APROKAM® and AZYTER®, and nutritional supplements under the Nutrof® brand. The company emphasizes its preservative-free formulations, with products available in both multi-dose ABAK® bottles and unit-dose vials.

Differentiator

Problem solved

Functional benefit

Brands

• ABAK: Multi-dose bottle technology capable of delivering preservative-free eye drops, developed after ten years of research in the 1990s.
• Nutrof

Products and services

• BLEPHASOL® Micellar lotion for daily hygiene of sensitive eyelids and lid margin. Removes impurities, debris, crusts, and makeup from the eyelid and lash line.
• BLEPHAGEL® Gel for daily hygiene of eyelids and lashes. Formula adapted for cleaning the lid margin when flaky and soiled with impurities.
• BLEPHADERM® Soothing cream for eyelids and eye contour area.
• BLEPHADEMODEX® Class IIa medical device recommended for eyelid hygiene in case of Demodex infection. Sterile, ready-to-use wipes for eyelid hygiene when affected by Demodex.
• BLEPHACLEAN® High-tolerance, preservative-free cleansing lotion. Sterile, pre-impregnated wipes recommended for daily eyelid hygiene and sensitive skin.
• BLEPHA EYEBAG® Product for eyelid care and treatment.
• APROKAM® Antibiotic eye product for treating ocular infections.
• AZYTER® 6 UNIDOSES Antibiotic eye drops in unit-dose vials for treating ocular infections.
• Nutrof® One of the pioneers in the ocular nutrition segment, Nutrof has become a reference in the field of nutritional supplements for eye health.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Initiative PharmaminorOthers · 1 January 2026Théa joined Initiative Pharma, a new French pharmaceutical industry alliance. This union brings together committed industrial players focused on investment and innovation in France, with a clear ambition to strengthen sovereignty in the pharmaceutical sector.

Scale indicators1 record

Recent moves1 record

Expansion highlights5 records

Direct peers

• Santen Pharmaceutical: Japanese specialty pharmaceutical company focused on ophthalmology with a global commercial footprint. Directly comparable to Théa as a prescription ophthalmic pharma specialist covering glaucoma, dry eye, and ocular surface diseases.

Broad incumbents

• Alcon: Global leader in eye care with pharmaceutical and surgical/device businesses spanning cataract, glaucoma, dry eye and contact lenses. Larger and more diversified incumbent serving the same ophthalmologist customers.
• Bausch + Lomb: Diversified ophthalmic company offering prescription ophthalmic pharmaceuticals, OTC eye care, and vision care products. Competes head-on with Théa in prescription eye drops and OTC eyelid hygiene.
• Allergan (AbbVie): Owner of the former Allergan Aesthetics/eye care franchise with leading ophthalmic pharmaceutical brands (e.g., RESTASIS, LUMIGAN). Targets the same ophthalmologist channel as Théa with significantly greater resources.
• Horizon Therapeutics: Specialty biopharma with significant ophthalmic franchise (TEPEZZA for thyroid eye disease). Competes for ophthalmologist prescribing and biologic ophthalmology indications adjacent to Théa's portfolio.

Emerging players

• Nicox: France-based ophthalmic specialty company developing therapeutics for glaucoma and ocular surface diseases. Closely comparable as a smaller, French-rooted ophthalmic pharma peer with overlapping therapeutic areas.
• Ocular Therapeutix: US-based biopharmaceutical company focused on ophthalmic therapeutics using innovative drug delivery platforms. Comparable as a smaller specialty player competing on differentiated ophthalmic delivery technology.
• EyePoint Pharmaceuticals: US specialty ophthalmic pharma commercializing sustained-release drug delivery treatments for retinal and ocular surface diseases. Overlaps with Théa in ophthalmic drug delivery innovation and prescriber channel.
• Kala Bio: US-based ophthalmic specialty pharma developing therapies for eye diseases. Comparable as a smaller ophthalmic-focused player competing for ophthalmologist mindshare in niche indications.

Regional players

• URSAPHARM: German-headquartered ophthalmic pharmaceutical company with a strong preservative-free and dry-eye portfolio. Directly comparable to Théa in European preservative-free ophthalmology and overlapping therapeutic categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Théa Pharma